Iloprost Rafarm

Iloprost, the active ingredient in Iloprost Rafarm, is a prostacyclin analog presented as an inhalation solution for inhalation use. It is indicated for the treatment of pulmonary arterial hypertension in adult patients, helping to lower pulmonary arterial pressure and improve exercise capacity.

GNH USA supplies Iloprost Rafarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions.

Iloprost is a prostacyclin analog that acts on the pulmonary vascular bed to reduce resistance and improve hemodynamics in pulmonary hypertension. - Pulmonary arterial hypertension: improves exercise capacity and delays disease progression. - Secondary pulmonary hypertension: provides vasodilation and symptom relief in patients with hypertension due to lung disease or left‑heart disease. - Post‑operative pulmonary hypertension: helps maintain stable pulmonary artery pressures after cardiac or lung surgery.

Iloprost may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cough: irritation of the airways leading to coughing during or after inhalation. - Throat irritation: discomfort or soreness in the throat. - Headache: mild to moderate headache episodes. - Flushing: warmth and redness of the face or neck. - Nausea: feeling of queasiness or upset stomach.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure that may cause dizziness. - Pulmonary edema: accumulation of fluid in the lungs, presenting with shortness of breath. - Bleeding: increased risk of hemorrhage due to platelet inhibition. - Severe bronchospasm: acute narrowing of the airways causing wheezing. - Arrhythmia: irregular heart rhythm that may require monitoring.

When prescribing Iloprost, clinicians should consider several precautionary measures to ensure patient safety. - Blood pressure monitoring: check for hypotension before and during therapy. - Bleeding risk assessment: evaluate patients on anticoagulants or with recent hemorrhage. - Respiratory status: avoid use in patients with active bronchospasm or severe asthma. - Liver function: monitor hepatic enzymes as metabolism may be affected. - Hemoptysis history: contraindicated in patients with recent coughing up blood. - Store at room temperature: keep in original container, protect from moisture and light.

Iloprost can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other vasodilators (e.g., nitroglycerin): additive hypotensive effect. - Endothelin receptor antagonists (e.g., bosentan): potential for severe hypotension.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal function. - Beta‑blockers: may mask tachycardia signs. - Diuretics: can enhance electrolyte disturbances.